Patents by Inventor Gro GAUSDAL

Gro GAUSDAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus
    Publication number: 20230149397
    Abstract: The present invention concerns an Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 18, 2023
    Applicant: BERGENBIO ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus
    Patent number: 11534440
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 27, 2022
    Assignee: BERGENBIO ASA
    Inventors: James Bradley Lorens, Gro Gausdal
  • COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
    Publication number: 20200215064
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 9, 2020
    Applicant: BerGenBio ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
    Publication number: 20180153888
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 7, 2018
    Applicant: BerGenBio ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL